Back to top
Top

All eCQMs associated with Management of Chronic Conditions

Year Type CMS eCQM ID Measure Name
2019 EP/EC CMS52v7 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
2019 EP/EC CMS122v7 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2020 EP/EC CMS122v8 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2021 EP/EC CMS122v9 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2019 EP/EC CMS131v7 Diabetes: Eye Exam
2020 EP/EC CMS131v8 Diabetes: Eye Exam
2021 EP/EC CMS131v9 Diabetes: Eye Exam
2019 EP/EC CMS132v7 Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
2019 EP/EC CMS133v7 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2020 EP/EC CMS133v8 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2021 EP/EC CMS133v9 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2019 EP/EC CMS134v7 Diabetes: Medical Attention for Nephropathy
2020 EP/EC CMS134v8 Diabetes: Medical Attention for Nephropathy
2021 EP/EC CMS134v9 Diabetes: Medical Attention for Nephropathy
2019 EP/EC CMS135v7 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2020 EP/EC CMS135v8 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2021 EP/EC CMS135v9 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2019 EP/EC CMS143v7 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2020 EP/EC CMS143v8 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2021 EP/EC CMS143v9 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation